Loading
Life sciences · Journal article
Theoretical and Natural Science · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ovarian cancer is one of the most deadly gynecologic cancers and is often detected at an advanced stage when the disease is disseminated. Initial disease control can be achieved with cytoreductive surgery and platinum-based chemotherapy, but recurrence is very common. Fluctuation of the CAR-T therapy in some types of hematologic malignancy has sparked interest in perhaps expanding this therapy to ovarian cancer; this is still to be seen. This review assesses the available clinical evidence without making the assumption that findings in blood cancers can be directly extrapolated to a solid tumor. Based on the level of evidence supporting each target, mesothelin, FRα, MUC16/CA125 and B7-H3 are considered. The results have been variable; and stable disease has been seen often, while significant regression and complete remissions are rare. Combination strategies, fertility issues and practical limitations that still remain in the use of CAR-T therapy in ovarian cancer are also discussed.